MedTrace Logo

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

NCT01334242 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2011-05-19

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the pharmacodynamics of LX4211 relative to meals in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Schedule A

Dosing 1 hour before breakfast

DRUG

Schedule B

Dosing 0.5 hour before breakfast

DRUG

Schedule C

Dosing immediately before breakfast

DRUG

Schedule D

Dosing immediately before lunch

DRUG

Schedule E

Split dose, dosing 1 hour before breakfast and dinner

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Ikenna Ogbaa, MD · Lexicon Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01334242 on ClinicalTrials.gov